论文部分内容阅读
目的:探讨孟鲁司特联合布地奈德气雾剂治疗小儿哮喘的临床效果。方法:选择我院近年来收治的84例哮喘患儿为研究对象,随机分为研究组和对照组,对照组给予布地奈德气雾剂吸入治疗,研究组在对照组治疗方法基础上采用孟鲁司特口服治疗,比较两组临床疗效及肺功能改善情况。结果:研究组临床疗效总有效率为95.2%,显著高于对照组总有效率为78.6%(P<0.05);两组FEV1和PEF治疗后均显著提高(P<0.05);且研究组治疗后肺功能FEV1和PEF指标均显著高于对照组(P<0.05)。结论:孟鲁司特联合布地奈德气雾剂治疗小儿哮喘,能够提高临床疗效,具有较高的临床应用价值。
Objective: To investigate the clinical effect of montelukast combined with budesonide aerosol in the treatment of pediatric asthma. Methods: Eighty-four asthmatic children admitted to our hospital in recent years were randomly divided into study group and control group. The control group was treated with budesonide aerosol inhalation. The study group was treated with the control group Lu Souter oral treatment, the two groups were compared the clinical efficacy and improvement of pulmonary function. Results: The total effective rate was 95.2% in the study group, significantly higher than that in the control group (78.6%, P <0.05). The FEV1 and PEF in both groups were significantly increased (P <0.05) The posterior pulmonary function FEV1 and PEF were significantly higher than the control group (P <0.05). Conclusion: Montelukast combined with budesonide aerosol treatment of pediatric asthma, can improve clinical efficacy, with high clinical value.